Mitoxantrone
- Generic Name
- Mitoxantrone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28N4O6
- CAS Number
- 65271-80-9
- Unique Ingredient Identifier
- BZ114NVM5P
- Background
An anthracenedione-derived antineoplastic agent.
- Indication
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma
- Associated Therapies
- Autologous hematopoietic stem cell transplant
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
- Conditions
- Recurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Mixed Phenotype Acute LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Myelodysplastic SyndromeRefractory Acute Leukemia of Ambiguous LineageRefractory Acute Undifferentiated Leukemia
- Interventions
- Drug: CyclophosphamideDrug: CladribineDrug: CyclosporineDrug: CytarabineDrug: Mycophenolate SodiumBiological: FilgrastimProcedure: Hematopoietic Cell TransplantationDrug: MitoxantroneDrug: IdarubicinDrug: Mycophenolate MofetilDrug: FludarabineRadiation: Total-Body IrradiationProcedure: Multigated Acquisition ScanProcedure: EchocardiographyProcedure: X-Ray ImagingProcedure: Bone Marrow BiopsyProcedure: Bone Marrow AspirationProcedure: Biospecimen Collection
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT04375631
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients
- Conditions
- Myeloid NeoplasmAcute Myeloid Leukemia
- Interventions
- Drug: Liposome-encapsulated Daunorubicin-CytarabineDrug: CladribineOther: Questionnaire AdministrationDrug: CytarabineBiological: Recombinant Granulocyte Colony-Stimulating FactorDrug: MitoxantroneOther: Quality-of-Life Assessment
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT04195945
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms
- Conditions
- Refractory Acute Myeloid LeukemiaMyeloid NeoplasmRecurrent Acute Myeloid Leukemia
- Interventions
- Drug: CladribineDrug: CytarabineBiological: Recombinant Granulocyte Colony-Stimulating FactorDrug: Mitoxantrone
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 13
- Registration Number
- NCT04196010
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Medium Dose of Cytarabine and Mitoxantrone
- Conditions
- ChemotherapyAcute Myelogenous Leukemia
- Interventions
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Shenzhen People's Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT04024241
- Locations
- 🇨🇳
Shenzhen, Shenzhen, Guangdong, China
Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyDrug: CytarabineProcedure: Echocardiogram RecordingDrug: Etoposide PhosphateDrug: Mitoxantrone HydrochlorideProcedure: Multigated Acquisition ScanDrug: Peposertib
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT03983824
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Delta-Fly Pharma, Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT03926624
- Locations
- 🇺🇸
University of California, Irvine, California, United States
🇺🇸Decatur Memorial Hospital-Cancer Care Specialists of Central IL, Decatur, Illinois, United States
🇺🇸The University of Mississippi Medical Center, Jackson, Mississippi, United States
Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia
- Interventions
- Drug: IsatuximabDrug: Dexamethasone or equivalentDrug: FludarabineDrug: CytarabineDrug: Liposomal daunorubicinDrug: Daunorubicin (nonliposomal)Drug: IdarubicinDrug: Filgrastim or equivalentDrug: MitoxantroneDrug: DoxorubicinDrug: VincristineDrug: Pegaspargase (PEG) AsparaginaseDrug: CyclophosphamideDrug: EtoposideDrug: MethotrexateDrug: L - AsparginaseDrug: HydroxyureaDrug: L - Asparaginase (Erwinase)
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 67
- Registration Number
- NCT03860844
- Locations
- 🇺🇸
Children's Medical Center of Dallas-Site Number:8400002, Dallas, Texas, United States
🇲🇽Investigational Site Number :4840001, Monterrey, Nuevo León, Mexico
🇧🇷Investigational Site Number :0760007, Porto Alegre, Rio Grande Do Sul, Brazil
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT03735446
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
- Conditions
- FLT3-mutated Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 23
- Registration Number
- NCT03591510
- Locations
- 🇹🇷
Novartis Investigative Site, Istanbul, Turkey
A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT03563560
- Locations
- 🇯🇵
Fukui University Hospital, Yoshida-gun, Fukui, Japan
🇯🇵Chugoku Central Hospital, Fukuyama, Hiroshima, Japan
🇯🇵Hokkaido University Hospital, Sapporo, Hokkaido, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.